Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 18, 2026
Why Is IM Cannabis Corp. (IMCC) Stock Up +166.67% Today?

Why Is IM Cannabis Corp. (IMCC) Stock Up +166.67% Today?

Key Takeaways

  • IMCC surged roughly +166.67% in Thursday's session, climbing from a prior close of $1.74 to about $4.64.
  • The rally was primarily momentum- and sentiment-driven, tied to renewed optimism around expanding legal cannabis markets.
  • A recent 30-for-1 share consolidation and a related divestiture of European assets have reshaped the company's capital structure, amplifying price volatility.
  • Volume spiked sharply, indicating heavy participation from retail and algorithmic traders.
  • Investors are watching whether the gains hold, given the stock's history of rapid, round-trip price swings.

Opening Summary

IMCC, the Nasdaq-listed common shares of IM Cannabis Corp., an international medical cannabis company with operations in Israel and Germany, posted an extraordinary single-session advance on Thursday. Shares climbed roughly 166.67%, rising from a prior closing price of $1.74 to trade near $4.64. The move marked a dramatic upward reversal for a micro-cap name that has been consolidating and restructuring in recent months. Market commentary attributed the surge primarily to a burst of speculative momentum and renewed enthusiasm around the global legal-cannabis theme, amplified by the stock's newly reduced share count and thin float.

Cannabis Sector Momentum and Legalization Optimism

The most immediate driver cited by traders was a broad lift in sentiment across the cannabis space, fueled by optimism over expanding legal-medical and adult-use markets. IM Cannabis has been leaning into growth in Germany following that country's medical cannabis liberalization, while maintaining its core Israeli medical cannabis distribution platform. When sector-wide enthusiasm builds, thinly traded small-cap cannabis names such as IMCC frequently experience outsized percentage moves, as capital rotates quickly into names perceived to offer the most leverage to a legalization catalyst.

Restructuring and Post-Consolidation Dynamics

The rally was amplified by significant recent corporate actions. The company completed a 30-for-1 share consolidation intended to support its Nasdaq listing compliance, sharply reducing the number of shares outstanding. In parallel, IM Cannabis agreed to divest its IMC Holdings and European-focused assets in a related-party transaction designed to improve shareholders' equity by roughly C$3 million and sharpen its focus on its retained Israeli medical cannabis operations. A reduced share count and a smaller effective float make the stock far more sensitive to even modest buying pressure, which helps explain the magnitude of Thursday's move.

Market Context and Trading Activity

Trading activity was exceptionally heavy, with volume running well above the stock's typical daily average. The move reflected a clear divergence from broader equity benchmarks, underscoring that it was a stock-specific, momentum-driven event rather than a reflection of general market conditions. Technically, shares blew through the multi-day consolidation range that had kept the stock in the low-to-mid single digits, recapturing levels not seen since a late-summer run. The speed and scale of the advance, however, are consistent with a "blow-off" pattern that frequently attracts day traders and momentum scanners and can reverse just as quickly.

What Comes Next for IMCC

The path forward for IMCC depends on several factors. Traders will be watching whether the company can sustain higher price levels following its restructuring, its progress in the German and Israeli medical cannabis markets, and any further developments on its Nasdaq listing compliance. Key risks include ongoing operating losses, a tight balance sheet with elevated short-term obligations, potential shareholder dilution from outstanding convertible notes, and geopolitical uncertainty in the Middle East, where the company's core operations are based. Given the stock's recent history of sharp, round-trip moves, volatility is likely to remain elevated in the near term.

Trending AI Robots

For investors seeking a more systematic approach to navigating volatile markets, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches tailored to different objectives. Consider reviewing the Trending AI Robots to see how automated strategies are adapting to today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IMCC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IMCC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IMCC turned positive on September 25, 2026. Looking at past instances where IMCC's MACD turned positive, the stock continued to rise in 33 of 37 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +159.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 166 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMCC as a result. In 80 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 10-day moving average for IMCC crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IMCC broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMCC entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.949) is normal, around the industry mean (43.873). P/E Ratio (0.000) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.13B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 25%. ADCT experienced the highest price growth at 47%, while SXTC experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 67%. For the same stocks of the Industry, the average monthly volume growth was 128% and the average quarterly volume growth was 122%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 57
SMR Rating: 86
Profit Risk Rating: 84
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
IMCC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
Central District
Phone
+972 773603504
Employees
44
Web
https://www.imcannabis.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.